{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T13:05:30Z","timestamp":1792242330237,"version":"4.4.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T00:00:00Z","timestamp":1710288000000},"content-version":"vor","delay-in-days":12,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100016198","name":"Idorsia Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016198","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s40268-024-00456-8","type":"journal-article","created":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T07:24:32Z","timestamp":1710314672000},"page":"97-108","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Effect of Daridorexant on the Pharmacokinetics of Midazolam, and on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Male Subjects"],"prefix":"10.1007","volume":"24","clinical-trial-number":[{"clinical-trial-number":"nct05480488","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8106-8087","authenticated-orcid":false,"given":"Isabelle","family":"Zenklusen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4083-5817","authenticated-orcid":false,"given":"Jasper","family":"Dingemanse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Reh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0780-1073","authenticated-orcid":false,"given":"Martine","family":"Gehin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2415-3012","authenticated-orcid":false,"given":"Priska","family":"Kaufmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,13]]},"reference":[{"issue":"3","key":"456_CR1","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1124\/jpet.117.241596","volume":"362","author":"A Treiber","year":"2017","unstructured":"Treiber A, De Kanter R, Roch C, Gatfield J, Boss C, Von Raumer M, et al. The use of physiology-based pharmacokinetic and pharmacodynamic modeling in the discovery of the dual orexin receptor antagonist ACT-541468. J Pharmacol Exp Ther. 2017;362(3):489\u2013503. https:\/\/doi.org\/10.1124\/jpet.117.241596.","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"456_CR2","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S1474-4422(21)00436-1","volume":"21","author":"E Mignot","year":"2022","unstructured":"Mignot E, Mayleben D, Fietze I, Leger D, Zammit G, Bassetti CLA, et al. Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials. Lancet Neurol. 2022;21(2):125\u201339. https:\/\/doi.org\/10.1016\/S1474-4422(21)00436-1.","journal-title":"Lancet Neurol"},{"key":"456_CR3","unstructured":"US FDA. Quviviq (daridorexant): dighlights of prescribing information. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/214985s000lbl.pdf. Accessed 10 Oct 2023."},{"key":"456_CR4","unstructured":"EMA. Quviviq (daridorexant): summary of product characteristics. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/quviviq-epar-product-information_en.pdf. Accessed 10 Oct 2023."},{"issue":"5","key":"456_CR5","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1002\/cpt.1046","volume":"104","author":"C Muehlan","year":"2018","unstructured":"Muehlan C, Heuberger J, Juif PE, Croft M, van Gerven J, Dingemanse J. Accelerated development of the dual orexin receptor antagonist ACT-541468: integration of a microtracer in a first-in-human study. Clin Pharmacol Ther. 2018;104(5):1022\u20139. https:\/\/doi.org\/10.1002\/cpt.1046.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"456_CR6","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s00228-018-2559-5","volume":"75","author":"ML Boof","year":"2019","unstructured":"Boof ML, Alatrach A, Ufer M, Dingemanse J. Interaction potential of the dual orexin receptor antagonist ACT-541468 with CYP3A4 and food: results from two interaction studies. Eur J Clin Pharmacol. 2019;75(2):195\u2013205. https:\/\/doi.org\/10.1007\/s00228-018-2559-5.","journal-title":"Eur J Clin Pharmacol"},{"issue":"7","key":"456_CR7","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.euroneuro.2019.05.009","volume":"29","author":"C Muehlan","year":"2019","unstructured":"Muehlan C, Brooks S, Zuiker R, van Gerven J, Dingemanse J. Multiple-dose clinical pharmacology of ACT-541468, a novel dual orexin receptor antagonist, following repeated-dose morning and evening administration. Eur Neuropsychopharmacol. 2019;29(7):847\u201357. https:\/\/doi.org\/10.1016\/j.euroneuro.2019.05.009.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"3","key":"456_CR8","doi-asserted-by":"publisher","first-page":"94","DOI":"10.3390\/JOX11030007","volume":"11","author":"F Esteves","year":"2021","unstructured":"Esteves F, Rueff J, Kranendonk M. The central role of cytochrome P450 in xenobiotic metabolism: a brief review on a fascinating enzyme family. J Xenobiotics. 2021;11(3):94. https:\/\/doi.org\/10.3390\/JOX11030007.","journal-title":"J Xenobiotics."},{"key":"456_CR9","unstructured":"EMA. Quviviq: Committee for Medicinal Products for Human Use (CHMP) Aasessment report. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/quviviq-epar-public-assessment-report_en.pdf. Accessed 10 Oct 2023."},{"issue":"6","key":"456_CR10","doi-asserted-by":"publisher","first-page":"483","DOI":"10.2165\/00003088-198611060-00005","volume":"11","author":"NHG Holford","year":"1986","unstructured":"Holford NHG. Clinical pharmacokinetics and pharmacodynamics of warfarin: understanding the dose-effect relationship. Clin Pharmacokinet. 1986;11(6):483\u2013504. https:\/\/doi.org\/10.2165\/00003088-198611060-00005.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"456_CR11","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0163-7258(96)00140-4","volume":"73","author":"LS Kaminsky","year":"1997","unstructured":"Kaminsky LS, Zhang ZY. Human P450 metabolism of warfarin. Pharmacol Ther. 1997;73(1):67\u201374. https:\/\/doi.org\/10.1016\/S0163-7258(96)00140-4.","journal-title":"Pharmacol Ther"},{"issue":"3","key":"456_CR12","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1097\/01.MBC.0000220247.97164.EA","volume":"17","author":"G Lippi","year":"2006","unstructured":"Lippi G, Montagnana M, Salvagno GL, Poli G, Franchini M, Guidi GC. Influence of warfarin therapy on activated factor VII clotting activity. Blood Coagul Fibrinolysis. 2006;17(3):221\u20134. https:\/\/doi.org\/10.1097\/01.MBC.0000220247.97164.EA.","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"11","key":"456_CR13","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1211\/0022357001777405","volume":"52","author":"IM Costa","year":"2000","unstructured":"Costa IM, Soares PJ, Afonso M, Ratado P, Lanao JM, Falc\u00e3o AC. Therapeutic monitoring of warfarin: the appropriate response marker. J Pharm Pharmacol. 2000;52(11):1405\u201310. https:\/\/doi.org\/10.1211\/0022357001777405.","journal-title":"J Pharm Pharmacol"},{"key":"456_CR14","unstructured":"Patel S, Singh R, Preuss CV, Patel N. Warfarin. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing; 2024. [Updated 2023 Mar 24]."},{"key":"456_CR15","unstructured":"US FDA. Coumadin: highlights of prescribing information. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/009218s107lbl.pdf. Accessed 22 Dec 2023."},{"issue":"3","key":"456_CR16","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/S40262-013-0115-0","volume":"53","author":"M Donzelli","year":"2014","unstructured":"Donzelli M, Derungs A, Serratore MG, Noppen C, Nezic L, Kr\u00e4henb\u00fchl S, et al. The basel cocktail for simultaneous phenotyping of human cytochrome P450 isoforms in plasma, saliva and dried blood spots. Clin Pharmacokinet. 2014;53(3):271\u201382. https:\/\/doi.org\/10.1007\/S40262-013-0115-0.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"456_CR17","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1111\/J.1365-2125.2006.02589.X","volume":"61","author":"D Ouellet","year":"2006","unstructured":"Ouellet D, Bramson C, Carvajal-Gonzalez S, Roman D, Randinitis E, Remmers A, et al. Effects of lasofoxifene on the pharmacokinetics and pharmacodynamics of single-dose warfarin. Br J Clin Pharmacol. 2006;61(6):741\u20135. https:\/\/doi.org\/10.1111\/J.1365-2125.2006.02589.X.","journal-title":"Br J Clin Pharmacol"},{"key":"456_CR18","volume-title":"Calculating the point estimate and confidence interval of Hodges-Lehmann\u2019s median using SAS software","author":"Han","year":"2008","unstructured":"Han. Calculating the point estimate and confidence interval of Hodges-Lehmann\u2019s median using SAS software. North Wales: Merck Co, Inc.; 2008."},{"issue":"5","key":"456_CR19","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/S0009-9236(03)00229-7","volume":"74","author":"S Chainuvati","year":"2003","unstructured":"Chainuvati S, Nafziger AN, Leeder JS, Gaedigk A, Kearns GL, Sellers E, et al. Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the \u2018Cooperstown 5+1 cocktail.\u2019 Clin Pharmacol Ther. 2003;74(5):437\u201347. https:\/\/doi.org\/10.1016\/S0009-9236(03)00229-7.","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"456_CR20","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1111\/J.1365-2125.2009.03548.X","volume":"68","author":"S Turpault","year":"2009","unstructured":"Turpault S, Brian W, Van Horn R, Santoni A, Poitiers F, Donazzolo Y, et al. Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A. Br J Clin Pharmacol. 2009;68(6):928\u201335. https:\/\/doi.org\/10.1111\/J.1365-2125.2009.03548.X.","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"456_CR21","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1002\/JCPH.1588","volume":"60","author":"B Berger","year":"2020","unstructured":"Berger B, Kaufmann P, Koch A, Dingemanse J. Impact of the selective orexin-1 receptor antagonist ACT-539313 on the pharmacokinetics of the CYP3A probe drug midazolam in healthy male subjects. J Clin Pharmacol. 2020;60(7):931\u201341. https:\/\/doi.org\/10.1002\/JCPH.1588.","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"456_CR22","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/S00228-012-1403-6","volume":"69","author":"M Hoch","year":"2013","unstructured":"Hoch M, Hoever P, Alessi F, Theodor R, Dingemanse J. Pharmacokinetic interactions of almorexant with midazolam and simvastatin, two CYP3A4 model substrates, in healthy male subjects. Eur J Clin Pharmacol. 2013;69(3):523\u201332. https:\/\/doi.org\/10.1007\/S00228-012-1403-6.","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"456_CR23","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/S40268-013-0017-5","volume":"13","author":"J Dingemanse","year":"2013","unstructured":"Dingemanse J, Hoever P. Absence of pharmacokinetic and pharmacodynamic interactions between almorexant and warfarin in healthy subjects. Drugs R D. 2013;13(2):145\u201351. https:\/\/doi.org\/10.1007\/S40268-013-0017-5.","journal-title":"Drugs R D."},{"issue":"8","key":"456_CR24","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/S40261-014-0207-0\/METRICS","volume":"34","author":"PN Sidharta","year":"2014","unstructured":"Sidharta PN, Dietrich H, Dingemanse J. Investigation of the effect of macitentan on the pharmacokinetics and pharmacodynamics of warfarin in healthy male subjects. Clin Drug Investig. 2014;34(8):545\u201352. https:\/\/doi.org\/10.1007\/S40261-014-0207-0\/METRICS.","journal-title":"Clin Drug Investig"},{"issue":"3","key":"456_CR25","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/S40263-019-00697-1","volume":"34","author":"M Richard","year":"2020","unstructured":"Richard M, Kaufmann P, Ort M, Kornberger R, Dingemanse J. Multiple-ascending dose study in healthy subjects to assess the pharmacokinetics, tolerability, and CYP3A4 interaction potential of the T-type calcium channel blocker ACT-709478, a potential new antiepileptic drug. CNS Drugs. 2020;34(3):311\u201323. https:\/\/doi.org\/10.1007\/S40263-019-00697-1.","journal-title":"CNS Drugs"},{"key":"456_CR26","unstructured":"EMA. Committee for Medicinal Products for Human Use (CHMP) guideline on the investigation of drug interactions. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-investigation-drug-interactions-revision-1_en.pdf. Accessed 10 Oct 2023."},{"key":"456_CR27","unstructured":"US FDA. Clinical drug interaction studies: cytochrome P450 enzyme- and transporter-mediated drug interactions guidance for industry. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/clinical-drug-interaction-studies-cytochrome-p450-enzyme-and-transporter-mediated-drug-interactions. Accessed 10 Oct 2023."},{"issue":"1","key":"456_CR28","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1021\/TX00025A009","volume":"5","author":"AE Rettie","year":"1992","unstructured":"Rettie AE, Korzekwa KR, Kunze KL, Lawrence RF, Eddy AC, Aoyama T, et al. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem Res Toxicol. 1992;5(1):54\u20139. https:\/\/doi.org\/10.1021\/TX00025A009.","journal-title":"Chem Res Toxicol"},{"issue":"8","key":"456_CR29","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1038\/BJP.2008.210","volume":"154","author":"MI Mohammed Abdul","year":"2008","unstructured":"Mohammed Abdul MI, Jiang X, Williams KM, Day RO, Roufogalis BD, Liauw WS, et al. Pharmacodynamic interaction of warfarin with cranberry but not with garlic in healthy subjects. Br J Pharmacol. 2008;154(8):1691. https:\/\/doi.org\/10.1038\/BJP.2008.210.","journal-title":"Br J Pharmacol"},{"issue":"1","key":"456_CR30","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1002\/PSP4.12877","volume":"12","author":"A Krause","year":"2023","unstructured":"Krause A, Lott D, Brussee JM, Muehlan C, Dingemanse J. Population pharmacokinetic modeling of daridorexant, a novel dual orexin receptor antagonist. CPT Pharmacometrics Syst Pharmacol. 2023;12(1):74. https:\/\/doi.org\/10.1002\/PSP4.12877.","journal-title":"CPT Pharmacometrics Syst Pharmacol"}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-024-00456-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40268-024-00456-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-024-00456-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T04:02:35Z","timestamp":1713844955000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40268-024-00456-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["456"],"URL":"https:\/\/doi.org\/10.1007\/s40268-024-00456-8","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"14 January 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was funded by Idorsia Pharmaceuticals Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the conduct of this study, Isabelle Zenklusen, Jasper Dingemanse, Martine Gehin, and Priska Kaufmann were employees at Idorsia Pharmaceuticals Ltd and Christian Reh was the principal investigator.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"The study was conducted in full conformity with the principles of the Declaration of Helsinki. The protocol was approved by the German Health Authority (BfArM) and by the local independent Ethics Committee (Ethik Kommission der Bayerischen Landes\u00e4rztekammer).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All subjects provided written informed consent prior to any study procedure.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The datasets generated and\/or analyzed during the study are available from the corresponding author on reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"IZ wrote the manuscript, IZ, JD, and MG designed the study, PK and JD analyzed the study, and CR was the principal investigator of the study. All authors revised the manuscript critically for important intellectual content and approved the version to be submitted.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}